THE EFFECT OF DIFFERENT TB DRUGS AND ANTIMICROBIAL AGENTS ON THE EFFICIENCY OF TREATMENT OF TUBERCULOSIS PATIENTS WITH MULTIPLE DRUG RESISTANCE

THE EFFECT OF DIFFERENT TB DRUGS AND ANTIMICROBIAL AGENTS ON THE EFFICIENCY OF TREATMENT OF TUBERCULOSIS PATIENTS WITH MULTIPLE DRUG RESISTANCE

Objective of the study: to study the effect of specific TB drugs and antimicrobial agents constituting chemotherapy regimens on the efficiency of treatment of tuberculosis patients with various patterns of multiple drug resistance.Subjects and Methods. 412 pulmonary tuberculosis patients with bacill...

Full description

Saved in:

Bibliographic Details
Main Authors:	I. A. Vasilyeva, A. G. Samoylova, O. V. Lovacheva, L. N. Chernousova, T. R. Bagdasaryan
Format:	Article
Language:	Russian
Published:	New Terra Publishing House 2017-11-01
Series:	Туберкулез и болезни лёгких
Subjects:	pulmonary tuberculosis mdr tb xdr tb tuberculosis chemotherapy linezolid bedaquiline fluoruquinolones
Online Access:	https://www.tibl-journal.com/jour/article/view/1048
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Justification of Chemotherapy Duration in Patients with Multiple and Pre-Extensive Drug Resistant Tuberculosis in the Russian Federation
by: A. I. Gayda, et al.
Published: (2023-01-01)

TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia
by: Laura Gillini, et al.
Published: (2013-03-01)

New drugs in the treatment of drug-resistant tuberculosis in children. Experience with the use of delamanid in combination with bedaquiline
by: Ekaterina Sokolskaya, et al.
Published: (2024-12-01)

QT-Interval Prolongation in the Treatment of Drug-Resistant Tuberculosis
by: A. V. Kukurika
Published: (2024-03-01)

Communicable Episode 20: Tuberculosis today
by: Kathryn Hostettler, et al.
Published: (2025-06-01)

Information counselling during treatment with ototoxic medications for TB: a call to action
by: K. Khoza-Shangase, et al.
Published: (2025-03-01)

Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort studyResearch in context
by: Yousra Kherabi, et al.
Published: (2025-09-01)

Prevalence and contributing factors of drug-resistant tuberculosis (DR-TB) in iran: a systematic review
by: Salman Daneshi, et al.
Published: (2025-08-01)

Short course treatment regimens for multiple drug resistant tuberculosis in Arkhangelsk, Murmansk and Belgorod Regions
by: A. О. Mаryandyshev, et al.
Published: (2019-08-01)

Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review
by: Michalik, Maciej, et al.
Published: (2025-06-01)

Efektivitas dan Efek Samping pada Terapi Multi-Drug-Resistant Tuberculosis (MDR-TB): Kajian Literatur
by: Dwi Arymbhi Sanjaya, et al.
Published: (2025-03-01)

Investigating the Mutations in atpE and Rv0678 Genes in Mycobacterium Tuberculosis Clinical Isolates
by: Nahid Madadi-Goli1, 2, 3, et al.
Published: (2023-12-01)

Impacts of MDR/XDR-TB on the global tuberculosis epidemic: Challenges and opportunities
by: Kai Ling Chin, et al.
Published: (2024-01-01)

The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG
by: E. M. Zhukova, et al.
Published: (2019-12-01)

Genotypic and Phenotypic Methods in the Detection of MDR-TB and Evolution to XDR-TB
by: Natalia Zaporojan, et al.
Published: (2025-07-01)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
by: Luigi R. Codecasa, et al.
Published: (2017-01-01)

A survey of the effectiveness of centralized consilia in providing advice on drug-resistant TB
by: A. Vasquez, et al.
Published: (2024-07-01)

TUBERCULOSIS WITH CONCURRENT HIV INFECTION IN RUSSIA: STATISTICS AND CORRELATIONS
by: E. B. Tsybikova, et al.
Published: (2019-01-01)

Eﬃcacy and safety of short course chemotherapy regimens in older children and adolescents with multiple and extensive drug resistant respiratory tuberculosis
by: L. V. Panova, et al.
Published: (2021-11-01)

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy
by: L. Kuksa, et al.
Published: (2025-03-01)

Perspectives of targeted chemotherapy with delamanid in the treatment regimens of those with multiple/extensive drug resistant tuberculosis. A success, chance or uncertainty?
by: Aleksey G. Naumov, et al.
Published: (2018-11-01)

Treatment results of patients with multiple and extensive drug resistance registered in 2012 in the Russian Federation and in the world
by: S. A. Sterlikov, et al.
Published: (2016-01-01)

Isoniazid-resistant TB and associated factors in Ethiopia
by: S. Moga, et al.
Published: (2025-06-01)

The New Definition and Epidemiology of Extensive Drug Resistant Tuberculosis in 2020
by: S. A. Sterlikov, et al.
Published: (2023-04-01)

XDR TB in South Africa - What lies ahead?
by: V. Thaver, et al.
Published: (2007-12-01)

Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021
by: E. S. Khimova, et al.
Published: (2023-07-01)

Evaluation of the multiple doses thiozonide’s pharmacokinetics in patients diagnosed with pulmonary tuberculosis with multidrug-resistant or extensively drug-resistant <i>Mycobacterium tuberculosis</i>
by: А. Yu. Savchenko, et al.
Published: (2024-01-01)

TB drug susceptibility testing in high fluoroquinolone resistance settings
by: F. Saluzzo, et al.
Published: (2024-05-01)

Global, regional, and national burden and trends of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in adolescents and adults aged 15–49 years from 2010 to 2021: insights from the global burden of disease study 2021
by: Kunping Cui, et al.
Published: (2025-07-01)

Direct drug susceptibility testing of Mycobacterium tuberculosis against primary anti-TB drugs in northern India
by: Anamika Gupta, et al.
Published: (2010-06-01)

Characterization of drug susceptibility of Mycobacterium tuberculosis isolated from new cases of tuberculosis concurrent with HIV infection
by: G. V. Panov, et al.
Published: (2015-02-01)

Impact of US funding cuts and stop work orders on TB services and research in South Africa
by: N. Ndjeka, et al.
Published: (2025-04-01)

Frequency and Structure of Drug Resistance of M. tuberculosis in Pulmonary and Extrapulmonary Tuberculosis
by: P. K. Yablonskiy, et al.
Published: (2024-03-01)

SIDE EFFECTS OF SECOND-LINE ANTITUBERCULOSIS DRUGS IN MULTI-DRUG RESISTANCE (MDR) TUBERCULOSIS PATIENTS
by: Nia Savitri Tamzil, et al.
Published: (2025-04-01)

Inhalation Surfactant Therapy within Comprehensive Treatment of HIV-Infected Patients with Multiple Drug Resistant Tuberculosis
by: E. M. Zhukova, et al.
Published: (2023-10-01)

Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings
by: A. V. Kukurika, et al.
Published: (2022-12-01)

Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials
by: J. Nedelman, et al.
Published: (2025-08-01)

Risk Factors for Multidrug-resistant Tuberculosis
by: Cleopas Martin Rumende
Published: (2018-04-01)

Risk Factors for Multidrug-resistant Tuberculosis
by: Cleopas Martin Rumende
Published: (2018-04-01)

Prevalence of drug resistance in clinical isolates of tuberculosis from GCC: a literature review from January 2002 to March 2013
by: Mohammed Yahya Areeshi, et al.
Published: (2014-09-01)